A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer
Jean A. Maroun(American Society of Clinical Oncology), G. Chiritescu(Ottawa Hospital), Horia Marginean(Ottawa Hospital), Derek J. Jonker(University of Ottawa), C. Cripps(Canadian Partnership Against Cancer), Rakesh Goel(Ottawa Hospital), Timothy R. Asmis(Ottawa Hospital), Rachel Goodwin(University of Ottawa)
Cited by 9
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k